重组酸性成纤维细胞生长因子可促进美国脊髓损伤协会损伤量表 A 型脊髓创伤患者的运动恢复并减少骨髓瘤。

IF 1.8 Q3 CLINICAL NEUROLOGY Neurotrauma reports Pub Date : 2024-10-02 eCollection Date: 2024-01-01 DOI:10.1089/neur.2024.0063
Wan-Ya Chang, Wen-Cheng Huang, Yun-An Tsai, Lin-Hsue Yang, Yi-Tien Su, Shih-Fong Huang, Chiau-Li Huang, Ya-Hui Lee, Shu-Shong Hsu, Li-Yu Fay
{"title":"重组酸性成纤维细胞生长因子可促进美国脊髓损伤协会损伤量表 A 型脊髓创伤患者的运动恢复并减少骨髓瘤。","authors":"Wan-Ya Chang, Wen-Cheng Huang, Yun-An Tsai, Lin-Hsue Yang, Yi-Tien Su, Shih-Fong Huang, Chiau-Li Huang, Ya-Hui Lee, Shu-Shong Hsu, Li-Yu Fay","doi":"10.1089/neur.2024.0063","DOIUrl":null,"url":null,"abstract":"<p><p>This study aims to evaluate the potential benefits of treating spinal cord injury (SCI) patients with acidic fibroblast growth factor (aFGF), a potent neurotrophic factor that preserves neuronal survival. The study involved 12 tetraplegic patients with American Spinal Injury Association Impairment Scale (AIS) Grade A SCI who were randomly assigned to receive either a recombinant human aFGF or a placebo every 4 weeks for three doses. Participants underwent comprehensive evaluations of medical, neurological, and functional parameters at baseline and every 4 weeks after the first dose until the 48th week. The first dose was administered directly to the injury site during surgery within 6 weeks of the SCI, while the subsequent two doses were administered via lumbar puncture with a 4-week interval. The results revealed promising beneficial effects of aFGF on AIS Grade A SCI patients. The study report highlights aFGF's potential to expedite motor recovery in complete SCI patients and significantly increase the probability of a 10-point improvement when compared to the placebo group (odds ratio = 6.06, <i>p</i> = 0.0004). Furthermore, aFGF treatment exhibited a significant reduction (<i>p</i> < 0.01) in the incidence or exacerbation rate of myelomalacia, a known secondary complication following SCIs.</p>","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"5 1","pages":"910-915"},"PeriodicalIF":1.8000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491575/pdf/","citationCount":"0","resultStr":"{\"title\":\"Recombinant Acidic Fibroblast Growth Factor Facilitates Motor Recovery and Reduces Myelomalacia in Traumatic American Spinal Injury Association Impairment Scale A Spinal Cord Injured Patients.\",\"authors\":\"Wan-Ya Chang, Wen-Cheng Huang, Yun-An Tsai, Lin-Hsue Yang, Yi-Tien Su, Shih-Fong Huang, Chiau-Li Huang, Ya-Hui Lee, Shu-Shong Hsu, Li-Yu Fay\",\"doi\":\"10.1089/neur.2024.0063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>This study aims to evaluate the potential benefits of treating spinal cord injury (SCI) patients with acidic fibroblast growth factor (aFGF), a potent neurotrophic factor that preserves neuronal survival. The study involved 12 tetraplegic patients with American Spinal Injury Association Impairment Scale (AIS) Grade A SCI who were randomly assigned to receive either a recombinant human aFGF or a placebo every 4 weeks for three doses. Participants underwent comprehensive evaluations of medical, neurological, and functional parameters at baseline and every 4 weeks after the first dose until the 48th week. The first dose was administered directly to the injury site during surgery within 6 weeks of the SCI, while the subsequent two doses were administered via lumbar puncture with a 4-week interval. The results revealed promising beneficial effects of aFGF on AIS Grade A SCI patients. The study report highlights aFGF's potential to expedite motor recovery in complete SCI patients and significantly increase the probability of a 10-point improvement when compared to the placebo group (odds ratio = 6.06, <i>p</i> = 0.0004). Furthermore, aFGF treatment exhibited a significant reduction (<i>p</i> < 0.01) in the incidence or exacerbation rate of myelomalacia, a known secondary complication following SCIs.</p>\",\"PeriodicalId\":74300,\"journal\":{\"name\":\"Neurotrauma reports\",\"volume\":\"5 1\",\"pages\":\"910-915\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2024-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491575/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurotrauma reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1089/neur.2024.0063\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurotrauma reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1089/neur.2024.0063","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

这项研究旨在评估用酸性成纤维细胞生长因子(aFGF)治疗脊髓损伤(SCI)患者的潜在益处,酸性成纤维细胞生长因子是一种有效的神经营养因子,能保护神经元存活。这项研究涉及12名美国脊髓损伤协会损伤量表(AIS)A级SCI四肢瘫痪患者,他们被随机分配接受重组人aFGF或安慰剂,每4周一次,共3次。参试者在基线时接受医疗、神经和功能参数的综合评估,并在首次给药后每 4 周接受一次评估,直至第 48 周。第一剂在脊髓损伤后6周内的手术中直接注射到损伤部位,随后两剂通过腰椎穿刺注射,间隔4周。研究结果表明,aFGF 对 AIS A 级 SCI 患者有很好的疗效。研究报告强调,aFGF 有可能加快完全性 SCI 患者的运动恢复,与安慰剂组相比,aFGF 能显著提高患者运动能力提高 10 分的概率(几率比 = 6.06,p = 0.0004)。此外,aFGF 治疗还显著降低了脊髓空洞症的发生率或恶化率(p < 0.01),而脊髓空洞症是脊髓损伤后的一种已知继发性并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Recombinant Acidic Fibroblast Growth Factor Facilitates Motor Recovery and Reduces Myelomalacia in Traumatic American Spinal Injury Association Impairment Scale A Spinal Cord Injured Patients.

This study aims to evaluate the potential benefits of treating spinal cord injury (SCI) patients with acidic fibroblast growth factor (aFGF), a potent neurotrophic factor that preserves neuronal survival. The study involved 12 tetraplegic patients with American Spinal Injury Association Impairment Scale (AIS) Grade A SCI who were randomly assigned to receive either a recombinant human aFGF or a placebo every 4 weeks for three doses. Participants underwent comprehensive evaluations of medical, neurological, and functional parameters at baseline and every 4 weeks after the first dose until the 48th week. The first dose was administered directly to the injury site during surgery within 6 weeks of the SCI, while the subsequent two doses were administered via lumbar puncture with a 4-week interval. The results revealed promising beneficial effects of aFGF on AIS Grade A SCI patients. The study report highlights aFGF's potential to expedite motor recovery in complete SCI patients and significantly increase the probability of a 10-point improvement when compared to the placebo group (odds ratio = 6.06, p = 0.0004). Furthermore, aFGF treatment exhibited a significant reduction (p < 0.01) in the incidence or exacerbation rate of myelomalacia, a known secondary complication following SCIs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.40
自引率
0.00%
发文量
0
审稿时长
8 weeks
期刊最新文献
Small Molecule Drug C381 Attenuates Brain Vascular Damage Following Repetitive Mild Traumatic Injury. Clinical Impact of an AI Decision Support System for Detection of Intracranial Hemorrhage in CT Scans. Metacognitive Therapy for People Experiencing Persistent Post-Concussion Symptoms Following Mild Traumatic Brain Injury: A Preliminary Multiple Case-Series Study. Multicenter Study Examining Temporal Trends in Traumatic Intracranial Hemorrhage Over Six Years Using Joinpoint Regression. Resilience and Concussion Recovery in Minority Women: Promoting Health Equity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1